Oramed Pharmaceuticals, Inc. Stock Xetra
Equities
OJU
US68403P1049
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
03:36pm | Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program | MT |
03:00pm | Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares. | CI |
Sales 2024 * | 750K 702K | Sales 2025 * | 2M 1.87M | Capitalization | 91.01M 85.24M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | -14M -13.11M | EV / Sales 2024 * | 121 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 45.5 x |
P/E ratio 2024 * |
-224
x | P/E ratio 2025 * |
-6.79
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.51% |
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 13-04-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 02-04-11 |
Miriam Kidron
FOU | Founder | 83 | 02-04-11 |
Leonard Sank
BRD | Director/Board Member | 59 | 07-10-22 |
1st Jan change | Capi. | |
---|---|---|
+25.65% | 52.73B | |
+37.49% | 39B | |
-8.84% | 38.52B | |
+28.03% | 30.38B | |
-12.26% | 26.39B | |
+10.37% | 26.08B | |
+44.80% | 14.15B | |
+32.48% | 12.6B | |
-6.32% | 11.51B |
- Stock Market
- Equities
- ORMP Stock
- OJU Stock